LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Treatment of critical bleeding events in patients with immune thrombocytopenia

    Emily Sirotich / Hasmik Nazaryan / Saifur Rahman Chowdhury / Gordon Guyatt / Arnav Agarwal / Russell Leong / Aaron Wen / Emily Xu / Bonnie Liu / Sushmitha Pallapothu / Preksha Rathod / Henry Y. Kwon / Jared Dookie / Amirmohammad Shafiee / Jay Charness / Jennifer DiRaimo / Dale Paynter / Barbara Pruitt / Gail Strachan /
    Rachel Couban / Zhikang Ye / Donald M. Arnold

    Systematic Reviews, Vol 13, Iss 1, Pp 1-

    a protocol for a systematic review and meta-analysis

    2024  Volume 6

    Abstract: Abstract Background Critical bleeding events in adults and children with ITP are medical emergencies; however, evidence-based treatment protocols are lacking. Due to the severe thrombocytopenia, (typically platelet count less than 20 × 109/L), a critical ...

    Abstract Abstract Background Critical bleeding events in adults and children with ITP are medical emergencies; however, evidence-based treatment protocols are lacking. Due to the severe thrombocytopenia, (typically platelet count less than 20 × 109/L), a critical bleed portends a high risk of death or disability. We plan to perform a systematic review and meta-analysis of treatments for critical bleeding in patients with ITP that will inform evidence-based recommendations. Methods Literature searches will be conducted in four electronic databases: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed. Eligible studies will be randomized controlled trials or observational studies that enrolled patients with ITP describing one or more interventions for the management of critical bleeding. Title and abstract screening, full-text screening, data extraction, and risk of bias evaluation will be conducted independently and in duplicate using Covidence and Excel. Outcomes will be pooled for meta-analysis where appropriate or summarized descriptively. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology will be used to evaluate the certainty of the evidence. Primary outcomes of interest will include frequency of critical bleeds, mortality and bleeding-related mortality, bleeding resolution, platelet count, and disability. Discussion Evidence-based treatments for critical bleeding in patients with ITP are needed to improve patient outcomes and standardize care in the emergency setting. Systematic review registration CRD42020161206.
    Keywords Immune thrombocytopenia ; Thrombocytopenia ; Emergency management ; Critical bleeding ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1)

    Philippe Bégin / Jeannie Callum / Nancy M. Heddle / Richard Cook / Michelle P. Zeller / Alan Tinmouth / Dean A. Fergusson / Melissa M. Cushing / Marshall J. Glesby / Michaël Chassé / Dana V. Devine / Nancy Robitalle / Renée Bazin / Nadine Shehata / Andrés Finzi / Allison McGeer / Damon C. Scales / Lisa Schwartz / Alexis F. Turgeon /
    Ryan Zarychanski / Nick Daneman / Richard Carl / Luiz Amorim / Caroline Gabe / Martin Ellis / Bruce S. Sachais / Kent Cadogan Loftsgard / Erin Jamula / Julie Carruthers / Joanne Duncan / Kayla Lucier / Na Li / Yang Liu / Chantal Armali / Amie Kron / Dimpy Modi / Marie-Christine Auclair / Sabrina Cerro / Meda Avram / Donald M. Arnold

    Trials, Vol 22, Iss 1, Pp 1-

    study protocol for an international, multicentre, randomized, open-label trial

    2021  Volume 17

    Abstract: Abstract Background Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is weak. SARS-CoV-2 is a ... ...

    Abstract Abstract Background Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is weak. SARS-CoV-2 is a novel coronavirus responsible for the 2019 global pandemic of COVID-19 community acquired pneumonia. We have undertaken a randomized controlled trial to assess the efficacy and safety of COVID-19 convalescent plasma (CCP) in patients with SARS-CoV-2 infection. Methods CONCOR-1 is an open-label, multicentre, randomized trial. Inclusion criteria include the following: patients > 16 years, admitted to hospital with COVID-19 infection, receiving supplemental oxygen for respiratory complications of COVID-19, and availability of blood group compatible CCP. Exclusion criteria are : onset of respiratory symptoms more than 12 days prior to randomization, intubated or imminent plan for intubation, and previous severe reactions to plasma. Consenting patients are randomized 2:1 to receive either approximately 500 mL of CCP or standard of care. CCP is collected from donors who have recovered from COVID-19 and who have detectable anti-SARS-CoV-2 antibodies quantified serologically. The primary outcome is intubation or death at day 30. Secondary outcomes include ventilator-free days, length of stay in intensive care or hospital, transfusion reactions, serious adverse events, and reduction in SARS-CoV-2 viral load. Exploratory analyses include patients who received CCP containing high titre antibodies. A sample size of 1200 patients gives 80% power to detect a 25% relative risk reduction assuming a 30% baseline risk of intubation or death at 30 days (two-sided test; α = 0.05). An interim analysis and sample size re-estimation will be done by an unblinded independent biostatistician after primary outcome data are available for 50% of the target recruitment (n = 600). Discussion This trial will determine whether CCP will reduce intubation or death non-intubated adults with ...
    Keywords Convalescent plasma ; SARS-CoV-2 ; Coronavirus ; COVID-19 ; Randomized controlled trial ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2021-05-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top